Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
- 11 June 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (9) , 2183-2189
Abstract
OBJECTIVE To assess the effects of empagliflozin, a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor, on broad biological systems through proteomics. RESEARCH DESIGN AND METHODS Aptamer-based proteomics was used to quantify 3,713 proteins in 144 paired plasma samples obtained from 72 participants across the spectrum of glucose tolerance before and after 4 weeks of empagliflozin 25 mg/day. The biology of the plasma proteins significantly changed by empagliflozin (at false discovery rate–corrected P < 0.05) was discerned through Ingenuity Pathway Analysis. RESULTS Empagliflozin significantly affected levels of 43 proteins, 6 related to cardiomyocyte function (fatty acid–binding protein 3 and 4 [FABPA], neurotrophic receptor tyrosine kinase, renin, thrombospondin 4, and leptin receptor), 5 to iron handling (ferritin heavy chain 1, transferrin receptor protein 1, neogenin, growth differentiation factor 2 [GDF2], and β2-microglobulin), and 1 to sphingosine/ceramide metabolism (neutral ceramidase), a known pathway of cardiovascular disease. Among the protein changes achieving the strongest statistical significance, insulin-like binding factor protein-1 (IGFBP-1), transgelin-2, FABPA, GDF15, and sulphydryl oxidase 2 precursor were increased, while ferritin, thrombospondin 3, and Rearranged during Transfection (RET) were decreased by empagliflozin administration. CONCLUSIONS SGLT2 inhibition is associated, directly or indirectly, with multiple biological effects, including changes in markers of cardiomyocyte contraction/relaxation, iron handling, and other metabolic and renal targets. The most significant differences were detected in protein species (GDF15, ferritin, IGFBP-1, and FABP) potentially related to the clinical and metabolic changes that were actually measured in the same patients. These novel results may inform further studies using targeted proteomics and a prospective design.Keywords
This publication has 40 references indexed in Scilit:
- Metabolic functions of FABPs—mechanisms and therapeutic implicationsNature Reviews Endocrinology, 2015
- Energy Balance After Sodium–Glucose Cotransporter 2 InhibitionDiabetes Care, 2015
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJournal of Clinical Investigation, 2014
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose productionJournal of Clinical Investigation, 2014
- Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic AgentsMolecular Therapy Nucleic Acids, 2014
- Increasing Circulating IGFBP1 Levels Improves Insulin Sensitivity, Promotes Nitric Oxide Production, Lowers Blood Pressure, and Protects Against AtherosclerosisDiabetes, 2012
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on MetforminThe Journal of Clinical Endocrinology & Metabolism, 2012
- Role of IGF-1 in glucose regulation and cardiovascular diseaseExpert Review of Cardiovascular Therapy, 2008
- Structure and Organization of the Human Thrombospondin 3 Gene (THBS3)Genomics, 1995
- Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence.Proceedings of the National Academy of Sciences, 1993